FY2028 EPS Estimates for 2seventy bio, Inc. (NASDAQ:TSVT) Increased by Analyst

2seventy bio, Inc. (NASDAQ:TSVT) – Stock analysts at Leerink Partnrs raised their FY2028 earnings per share estimates for 2seventy bio in a report released on Sunday, April 7th. Leerink Partnrs analyst D. Graybosch now forecasts that the company will post earnings per share of $2.52 for the year, up from their previous forecast of $2.50. Leerink Partnrs has a “Outperform” rating on the stock. The consensus estimate for 2seventy bio’s current full-year earnings is ($1.36) per share.

A number of other brokerages have also commented on TSVT. Citigroup lifted their price target on 2seventy bio from $9.00 to $12.00 and gave the company a “buy” rating in a research note on Monday. Wedbush reissued a “neutral” rating and set a $5.00 price target on shares of 2seventy bio in a research note on Monday, March 18th. SVB Leerink raised 2seventy bio from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $5.00 to $18.00 in a research note on Wednesday, January 31st. Finally, TD Cowen reissued a “market perform” rating on shares of 2seventy bio in a research note on Wednesday, January 31st. Five analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $13.17.

2seventy bio Stock Down 7.1 %

NASDAQ:TSVT opened at $5.23 on Tuesday. The stock’s 50-day simple moving average is $5.27 and its 200 day simple moving average is $3.95. 2seventy bio has a twelve month low of $1.53 and a twelve month high of $12.69. The firm has a market capitalization of $268.35 million, a PE ratio of -1.18 and a beta of 1.84.

2seventy bio (NASDAQ:TSVT) last released its quarterly earnings data on Tuesday, March 5th. The company reported ($1.11) earnings per share for the quarter, beating the consensus estimate of ($1.22) by $0.11. The business had revenue of $10.68 million for the quarter, compared to analyst estimates of $13.91 million. 2seventy bio had a negative return on equity of 59.19% and a negative net margin of 216.73%. During the same period last year, the firm posted ($0.60) earnings per share.

Hedge Funds Weigh In On 2seventy bio

A number of hedge funds and other institutional investors have recently made changes to their positions in TSVT. JPMorgan Chase & Co. acquired a new position in shares of 2seventy bio in the first quarter worth approximately $8,237,000. Bank of New York Mellon Corp bought a new stake in 2seventy bio in the first quarter worth approximately $1,493,000. Group One Trading L.P. bought a new stake in 2seventy bio in the first quarter worth approximately $69,000. Citigroup Inc. bought a new stake in 2seventy bio in the first quarter worth approximately $639,000. Finally, MetLife Investment Management LLC bought a new stake in 2seventy bio in the first quarter worth approximately $221,000. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Casdin Capital, Llc acquired 330,000 shares of the business’s stock in a transaction that occurred on Monday, March 25th. The shares were bought at an average cost of $5.07 per share, with a total value of $1,673,100.00. Following the completion of the purchase, the director now directly owns 1,960,000 shares in the company, valued at $9,937,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.60% of the stock is owned by insiders.

About 2seventy bio

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.